Zobrazeno 1 - 10 of 64 pro vyhledávání: '"Rena, Morita"'
1
Akademický článek
Establishment of potent TCR-T cells specific for cisplatin-resistance related tumor-associated antigen, CLSPN using codon-optimization
Autor: Kanta Hori, Shuhei Yamada, Kenji Murata, Haruka Miyata, Yuka Mizue, Aiko Murai, Tomoyuki Minowa, Kenta Sasaki, Naoki Shijubou, Terufumi Kubo, Rena Morita, Serina Tokita, Takayuki Kanaseki, Tomohide Tsukahara, Takashige Abe, Nobuo Shinohara, Yoshihiko Hirohashi, Toshihiko Torigoe
Publikováno v: Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
Adoptive T cell therapy, using T cell receptor-engineered T (TCR-T) cells and chimeric antigen receptor T (CAR-T) cells, is a potent immunotherapy option. Bladder cancer is a prevalent urological malignancy, particularly in cases of muscle invasion a
Externí odkaz: https://doaj.org/article/269c9bd4b49446de98270f0bc2134d49
Zobrazit plný text záznamu
2
Akademický článek
Immunopathological basis of immune-related adverse events induced by immune checkpoint blockade therapy
Autor: Terufumi Kubo, Yoshihiko Hirohashi, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Rena Morita, Toshihiko Torigoe
Publikováno v: Immunological Medicine, Vol 0, Iss 0, Pp 1-11 (2021)
Despite the considerable success of cancer immunotherapy with immune checkpoint inhibitors, their nonspecific release of the immunosuppressive mechanism is often associated with immune-related adverse events (irAEs). irAEs significantly disturb patie
Externí odkaz: https://doaj.org/article/44d134e8443c48ef80f9d6ca498f209d
Zobrazit plný text záznamu
3
Akademický článek
Fatal fulminant hepatitis induced by combined ipilimumab and nivolumab therapy despite favorable histologic response and confirmed by autopsy in a patient with clear cell renal cell carcinoma
Autor: Terufumi Kubo, Taro Sugawara, Tomoyo Shinkawa, Tomoyo Kurisu, Nodoka Kouzen, Toshiaki Tanaka, Fumimasa Fukuta, Kouji Yamasaki, Shintaro Sugita, Kazuhiko Matsuo, Rena Morita, Yoshihiko Hirohashi, Tomohide Tsukahara, Takayuki Kanaseki, Tadashi Hasegawa, Naoya Masumori, Toshihiko Torigoe
Publikováno v: Immunological Medicine, Vol 44, Iss 2, Pp 136-141 (2021)
Effective management of immune-related adverse events in patients receiving immunotherapy for cancer is problematic. In this report, we present the case of a 58-year-old man with advanced clear cell renal cell carcinoma who responded well to a combin
Externí odkaz: https://doaj.org/article/df76912d07174c658434da11e8f06dbd
Zobrazit plný text záznamu
5
Akademický článek
Non‐bacterial cystitis with increased expression of programmed death‐ligand 1 in the urothelium: An unusual immune‐related adverse event during treatment with pembrolizumab for lung adenocarcinoma
Autor: Yohei Ueki, Masahiro Matsuki, Terufumi Kubo, Rena Morita, Yoshihiko Hirohashi, Syunsuke Sato, Ryota Horibe, Kazuhiko Matsuo, Tomohide Tsukahara, Takayuki Kanaseki, Yasunari Takakuwa, Masaaki Satoh, Naoki Itoh, Toshihiko Torigoe
Publikováno v: IJU Case Reports, Vol 3, Iss 6, Pp 266-269 (2020)
Introduction Immune checkpoint inhibitors are now a standard therapeutic option for lung adenocarcinoma. However, Immune checkpoint inhibitors often induce various immune‐related adverse events. Case presentation The patient was a 78‐year‐old w
Externí odkaz: https://doaj.org/article/f20c3594a9e24922ab0dbfcfbdd3dcf8
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje